Listen Live

Brian Mann

Copyright 2021 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

President Biden announced a plan today to boost the supply of COVID-19 vaccines. He says the government is buying 200 million more and that it's working with states to get them out efficiently. Here to talk about these plans is NPR's Pien Huang.

The Trump administration introduced new addiction treatment guidelines Thursday that give physicians more flexibility to prescribe a drug to patients struggling with opioid addiction.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

When Ashwani Sheoran showed up for early morning shifts at pharmacies in rural Michigan wearing his white Walmart smock, he often found customers waiting, desperate for bottles of pain pills.

"I see my patients, 15 to 20, already lined up to get prescriptions filled for morphine sulfate, oxycodone and other straight narcotics," he said.

This was in 2012 when the prescription opioid epidemic was exploding, killing tens of thousands of Americans every year.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

Updated at 1:22 p.m. ET

Members of the Sackler family and Purdue Pharma's CEO say they did nothing wrong during the years their company illegally marketed Oxycontin and other opioids.

"There's nothing I can find that I would have done differently," said Dr. Kathe Sackler who served on Purdue's board for nearly 20 years.

One of the world's most influential corporate consulting firms, McKinsey & Company, says it regrets efforts to boost sales of OxyContin and other highly addictive opioids.

The rare apology follows revelations in documents made public last month for the first time that showed McKinsey working closely with Purdue Pharma and members of the Sackler family who sat on Purdue's board.

Updated at 7:20 p.m. ET

Newly public documents paint a detailed and often damning portrait of the role played by members of the Sackler family, owners of Purdue Pharma, during years when the privately owned drug company launched criminal schemes designed to "turbocharge" sales of Oxycontin and other highly addictive opioid medications.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST: